On this podcast, In Vivo's Jo Shorthouse is joined by Rebekah Martin, senior vice president of reward, inclusion, and talent acquisition at AstraZeneca to talk about the ways that pharma should be encouraging a diverse and inclusive team of young talent, and that strong connection between diversity of thought and innovation.

Building a narrow set of products and services that provide reliable and consistent revenue is a perfectly sound business strategy and one that sustains many biotech companies. But for the hungrier, like Twist Bioscience, Inc., a strategy of ongoing disruption and evolution has been more appealing and indeed is generating significant growth. Emily Leproust, Twist’s CEO, spoke with In Vivo about what it means to follow a value-added business strategy.

Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to In Vivo sister publication Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.

A selection of articles you might have missed from September 2022, including highlights from In Vivo's spotlight on rare diseases, their diagnosis and treatment.

After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.

Rare diseases are an underserved target for innovation, but development and commercialization hurdles can be staggering.

On this podcast, In Vivo's Jo Shorthouse is joined by Rebekah Martin, senior vice president of reward, inclusion, and talent acquisition at AstraZeneca to talk about the ways that pharma should be encouraging a diverse and inclusive team of young talent, and that strong connection between diversity of thought and innovation.

A selection of articles you might have missed from September 2022, including highlights from In Vivo's spotlight on rare diseases, their diagnosis and treatment.

Leading the company with the only therapy approved for NTM lung disease, Will Lewis tells In Vivo that success comes from giving researchers room to breath, visualizing patient benefit, and sailing into uncharted waters.

The US Supreme Court has overturned Roe v. Wade, but numerous avenues could help to preserve access to abortion drug mifepristone – if legislators and lawmakers are willing to walk down them.

Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.

Leaving commercial hires to just a few months before drug approval is a mistake, Argenx CEO Tim Van Hauwermeiren told In Vivo sister publication Scrip, noting that the impressive launch achieved for Vyvgart for generalized myasthenia gravis in the US and Japan will be a steadier affair in Europe.

Decentralized trials took a leap in popularity over the past few years, in part thanks to the COVID-19 pandemic. In Vivo's sister publication Medtech Insight spoke to two executives at clinical research technology companies about running decentralized clinical trials to discuss the benefits and limitations of trials run remotely.

The most recent FDA guidance on the use of real-world data in regulatory decision making is fundamental for patient advocacy organizations, ensuring that the FDA endorses drugs or biological products that lead to proper health outcomes without the risk of life-threatening side effects. 

The height of the summer saw eight $1bn plus deals penned, including those by Pfizer and Roche.